vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients

被引：0
|
作者：
Marino, M. [1 ]
Domenis, R. [2 ]
Biribin, L. [1 ]
Cifu, A. [2 ]
Navarria, L. [1 ]
Scardino, G. [1 ]
Fabris, M. [2 ]
机构：
[1] Azienda Sanit Univ Integrata Udine, Dept Gastroenterol, Udine, Italy
[2] Azienda Sanit Univ Integrata Udine, Ist Patol Clin, Udine, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P588
引用
收藏
页码：S492 / S492
页数：1
相关论文
共 50 条
  • [31] Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
    Levartovsky, Asaf
    Cohen, Ido
    Abitbol, Chaya Mushka
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Kopylov, Uri
    Ben-Horin, Shomron
    Ungar, Bella
    BIOMEDICINES, 2023, 11 (06)
  • [32] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [33] Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
    Singh, Namita
    Rosenthal, Casey J.
    Melmed, Gil Y.
    Mirocha, James
    Farrior, Sharmayne
    Callejas, Silvia
    Tripuraneni, Bhavna
    Rabizadeh, Shervin
    Dubinsky, Marla C.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1708 - 1713
  • [34] Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
    Serra, K.
    Rodriguez-Alonso, L.
    Padulles, N.
    Rodriguez-Moranta, F.
    Arajol, C.
    Gilabert, P.
    Rodriguez, R.
    Bas, J.
    Morandeira-Rego, F.
    Santacana, E.
    Padulles, A.
    Guardiola, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S358 - S358
  • [35] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [36] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [37] Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
    Plevris, Nikolas
    Jenkinson, Philip W.
    Chuah, Cher S.
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 117 - 123
  • [38] Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients
    Zelinkova, Z.
    Lipovska, A.
    Otottova, K.
    Lucenicova, J.
    Kadleckova, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S460 - S461
  • [39] Impact of Ustekinumab Trough Levels on Clinical Outcomes in Patients With Inflammatory Bowel Disease
    Nolan, Lindsey
    Meadors, Crystal
    Mcpheeters, Chelsey
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S18 - S19
  • [40] Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab
    Christensen, Britt
    Rubin, David T.
    Goeppinger, Sarah
    Colman, Ruben J.
    Yarur, Andres
    Hirsch, Ayal
    Bocheneck, Ashley
    Wichmann, Alana
    Sakuraba, Atsushi
    Cohen, Russell
    Siddiqui, Dania
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S783 - S784
12345